Table 2 |
||||||
|
WOMAC subscales in patients with inflammatory osteoarthritis of the knee who received open-label adalimumab |
||||||
|
Baseline |
4 weeks |
8 weeks |
12 weeks |
P valuea |
22 weeksb |
|
|
|
||||||
|
WOMAC pain |
60.8 (17.5) |
49.6 (21.0) |
40.2 (23.4) |
36.1 (23.6) |
< 0.0001 |
41.5 (18.9) |
|
WOMAC stiffness |
69.7 (16.3) |
58.5 (18.3) |
44.1 (26.0) |
37.0 (25.1) |
< 0.0001 |
48.6 (20.1) |
|
WOMAC function |
66.0 (19.4) |
53.2 (20.3) |
41.1 (25.8) |
39.2 (25.1) |
< 0.0001 |
46.6 (21.3) |
|
|
||||||
|
Mean (standard deviation) for Western Ontario and McMaster University Osteoarthritis Index (WOMAC) subscales over 22 weeks in 20 patients with inflammatory osteoarthritis of the knee who received open-label adalimumab for 12 weeks. aWeek 12 data versus baseline according to paired t test using last-observation-carried-forward data. bWeek 22 data are based on 16 patients who attended for assessment. |
||||||
|
Maksymowych et al. Arthritis Research & Therapy 2012 14:R206 doi:10.1186/ar4044 |
||||||
